TABLE 2

Post-bronchodilator forced expiratory volume in 1 s (FEV₁) slope during the 52-week treatment period (after week 4) across different patient subgroups

	1.14 mL/200 mg every 2 weeks		2 mL/300 mg every 2 weeks
	Placebo	Dupilumab	Placebo	Dupilumab
ITT population	317	631	321	633
Subjects	311	622	319	626
Post-bronchodilator FEV₁ slope after week 4^# L·year⁻¹	−0.038±0.453	0.001±0.393	−0.075±0.737	0.009±0.442
Estimated post-bronchodilator FEV₁ slope^¶ ±se	−0.04±0.02	−0.00±0.01	−0.04±0.02	−0.00±0.01
LS mean difference versus matched placebo (95% CI)		0.04 (0.00–0.08)		0.04 (0.00–0.08)
p-value versus matched placebo		0.04		0.04
Patients with ≥150 blood eosinophils·µL⁻¹ at baseline	232	437	237	452
Subjects	228	432	235	447
Post-bronchodilator FEV₁ slope after week 4^# L·year⁻¹	−0.038±0.487	−0.003±0.350	−0.086±0.842	−0.006±0.447
Estimated post-bronchodilator FEV₁ slope^¶ ±se	−0.04±0.02	0.00±0.01	−0.04±0.02	−0.01±0.01
LS mean difference versus matched placebo (95% CI)		0.04 (−0.01–0.09)		0.03 (−0.02–0.08)
p-value versus matched placebo		0.08		0.18
Patients with ≥300 blood eosinophils·µL⁻¹ at baseline	148	264	142	277
Subjects	146	261	142	274
Post-bronchodilator FEV₁ slope after week 4^# L·year⁻¹	−0.025±0.525	−0.008±0.355	−0.160±1.006	−0.012±0.533
Estimated post-bronchodilator FEV₁ slope^¶ ±se	−0.05±0.03	−0.02±0.02	−0.07±0.03	−0.01±0.02
LS mean difference versus matched placebo (95% CI)		0.03 (−0.03–0.09)		0.06 (−0.01–0.12)
p-value versus matched placebo		0.37		0.09
Patients with ≥25 ppb F_eNO at baseline	162	299	172	310
Subjects	159	295	171	306
Post-bronchodilator FEV₁ slope after week 4^# L·year⁻¹	−0.019±0.530	0.016±0.446	−0.098±0.958	−0.007±0.405
Estimated post-bronchodilator FEV₁ slope^¶ ±se	−0.02±0.03	0.00±0.02	−0.06±0.03	−0.01±0.02
LS mean difference versus matched placebo (95% CI)		0.03 (−0.04–0.09)		0.05 (−0.02–0.11)
p-value versus matched placebo		0.42		0.14
Patients with ≥150 blood eosinophils·µL⁻¹ and ≥25 ppb F_eNO at baseline	134	248	142	258
Subjects	132	245	141	255
Post-bronchodilator FEV₁ slope after week 4^# L·year⁻¹	−0.002±0.562	0.008±0.347	−0.102±1.043	−0.014±0.413
Estimated post-bronchodilator FEV₁ slope^¶ ±se	−0.01±0.03	0.00±0.02	−0.05±0.03	−0.02±0.02
LS mean difference versus matched placebo (95% CI)		0.01 (−0.06–0.08)		0.03 (−0.04–0.10)
p-value versus matched placebo		0.71		0.36

Data are presented as n or mean±sd, unless otherwise stated. ITT: intention-to-treat; LS: least squares; F_eNO, fractional exhaled nitric oxide. ^#: individual post-bronchodilator FEV₁ slope was calculated as the slope of a linear regression model with the post-bronchodilator FEV₁ (L) at each visit as the response variable and the time since randomisation as the independent variable; ^¶: estimated from a mixed-effects model with repeated measure with post-bronchodilator FEV₁ as outcome, and treatment, age, sex, height, geographic region, baseline eosinophil strata, baseline inhaled corticosteroid dose level, time since randomisation and treatment-by-time interaction and baseline post-bronchodilator as variables.